Francesco Cribari
Francesco Cribari is an expert in Cardiology at Istituto Dermopatico dell'Immacolata (Italy). Francesco Cribari has authored 9 publications, the most recent in 2026. SLR score: 31 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Biochemistry - Oncology - Internal Medicine
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2023 - 2026
Number : 9
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Correction to: The Role of Echocardiography in the Assessment of Epicardial Adipose Tissue: A Systematic Review and Meta-analysis. PMID 42858223 — echocardiography, obesity, tissues, adipose tissue | Curr Obes Rep | 2026 | 0 |
| MicroRNAs and Alarmins in Cardio-Oncology: Biomarkers and Therapeutic Implications in Skin and Breast Cancer. PMID 42794756 — skin, breast neoplasms, micrornas, stress, physiological, cardiovascular diseases, neoplasms, alarmins, biomarkers, breast, cardiotoxicity, therapeutics, cardio-oncology | Int J Mol Sci | 2026 | 0 |
| Cholesterol Metabolism in Cancer Patients: Mechanisms, Treatment-Related Effects, and Cardio-Oncology Management. PMID 42769788 — homeostasis, neoplasms, cholesterol, research, therapeutics, cardio-oncology | Oncol Res | 2026 | 0 |
| The Role of Echocardiography in the Assessment of Epicardial Adipose Tissue: A Systematic Review and Meta-analysis. PMID 42489846 — phenotype, heart failure, diastolic, echocardiography, obesity, tissues, adipose tissue | Curr Obes Rep | 2026 | 0 |
| SIMVASTATIN as a potential protective strategy against doxorubicin-induced cardiotoxicity. PMID 42344364 — simvastatin, doxorubicin, drug therapy, cholesterol, heart failure, systolic, cardiotoxicity, anthracyclines, therapeutics, hydroxymethylglutaryl-coa reductase inhibitors, chemotherapy | Front Cardiovasc Med | 2026 | 0 |
LeadR Networks
Main global connection map